PMV PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
PMV PHARMACEUTICALS, INC. (PMVP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.90 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 252.38K shares, a 16.32% decline year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 3.65M shares, a 4.68% increase year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 3.78M shares, a 40.23% decline from fiscal 2024.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 6.33M shares, a 207.06% increase from fiscal 2023.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 2.06M shares, a 45.30% increase from fiscal 2022.
- PMV PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.42M shares, a 75.82% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 252.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | 3.90M shares 10-Q · filed 2026-08-14 | 3.90M shares derived: sum of 3 quarters · filed 2026-08-14 | 3.90M shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | 3.65M shares 10-Q · filed 2026-05-12 | 3.65M shares derived: sum of 2 quarters · filed 2026-05-12 | 3.65M shares derived: sum of 3 quarters · filed 2026-05-12 | 3.95M shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-06 | 301.60K shares derived: sum of 3 quarters · filed 2026-03-06 | 3.78M shares 10-K · filed 2026-03-06 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 301.60K shares derived: sum of 2 quarters · filed 2025-11-12 | 3.78M shares 10-Q · filed 2025-11-12 | 3.85M shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 301.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 3.78M shares 10-Q · filed 2025-08-07 | 3.85M shares derived: sum of 3 quarters · filed 2025-08-07 | 6.80M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 3.48M shares 10-Q · filed 2025-05-09 | 3.55M shares derived: sum of 2 quarters · filed 2025-05-09 | 6.49M shares derived: sum of 3 quarters · filed 2025-05-09 | 7.04M shares derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-12-31 | 70.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 3.01M shares derived: sum of 2 quarters · filed 2025-03-03 | 3.56M shares derived: sum of 3 quarters · filed 2025-03-03 | 6.33M shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 2.94M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 3.49M shares derived: sum of 2 quarters · filed 2024-11-07 | 6.26M shares 10-Q · filed 2024-11-07 | 6.30M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 545.04K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 3.32M shares 10-Q · filed 2024-08-08 | 3.36M shares derived: sum of 3 quarters · filed 2024-08-08 | 3.50M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 2.78M shares 10-Q · filed 2024-05-09 | 2.82M shares derived: sum of 2 quarters · filed 2024-05-09 | 2.96M shares derived: sum of 3 quarters · filed 2024-05-09 | 4.79M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 40.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 180.00K shares derived: sum of 2 quarters · filed 2024-02-29 | 2.01M shares derived: sum of 3 quarters · filed 2024-02-29 | 2.06M shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 140.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 1.97M shares derived: sum of 2 quarters · filed 2023-11-09 | 2.02M shares 10-Q · filed 2023-11-09 | 2.14M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 1.83M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 1.88M shares 10-Q · filed 2023-08-09 | 2.00M shares derived: sum of 3 quarters · filed 2023-08-09 | 2.03M shares derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | 50.00K shares 10-Q · filed 2023-05-10 | 172.40K shares derived: sum of 2 quarters · filed 2023-05-10 | 201.20K shares derived: sum of 3 quarters · filed 2023-05-10 | 377.70K shares derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | 122.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | 151.20K shares derived: sum of 2 quarters · filed 2023-03-01 | 327.70K shares derived: sum of 3 quarters · filed 2023-03-01 | 1.42M shares 10-K · filed 2023-03-01 |
| 2022-09-30 | 28.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 205.30K shares derived: sum of 2 quarters · filed 2022-11-08 | 1.30M shares 10-Q · filed 2022-11-08 | 1.39M shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 176.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 1.27M shares 10-Q · filed 2022-08-09 | 1.36M shares derived: sum of 3 quarters · filed 2022-08-09 | 1.37M shares derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | 1.09M shares 10-Q · filed 2022-05-10 | 1.18M shares derived: sum of 2 quarters · filed 2022-05-10 | 1.20M shares derived: sum of 3 quarters · filed 2022-05-10 | 1.88M shares derived: sum of 4 quarters · filed 2022-05-10 |
| 2021-12-31 | 91.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | 103.91K shares derived: sum of 2 quarters · filed 2022-03-01 | 783.68K shares derived: sum of 3 quarters · filed 2022-03-01 | 807.18K shares 10-K · filed 2022-03-01 |
| 2021-09-30 | 12.11K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 691.88K shares derived: sum of 2 quarters · filed 2021-11-12 | 715.38K shares 10-Q · filed 2021-11-12 | 749.57K shares derived: sum of 4 quarters · filed 2021-11-12 |
| 2021-06-30 | 679.77K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | 703.27K shares 10-Q · filed 2021-08-13 | 737.47K shares derived: sum of 3 quarters · filed 2021-08-13 | |
| 2021-03-31 | 23.50K shares 10-Q · filed 2021-05-14 | 57.69K shares derived: sum of 2 quarters · filed 2021-05-14 | ||
| 2020-12-31 | 34.19K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | 1.38M shares 10-K · filed 2021-03-03 | ||
| 2020-09-30 | 1.34M shares 10-Q · filed 2020-11-13 | |||
| 2019-12-31 | 249.76K shares 10-K · filed 2021-03-03 | |||
| 2018-12-31 | 119.01K shares 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |